← Wiki Index / Microbiology & Immunology / T Helper 22 Cell
🦠 Microbiology & Immunology

T Helper 22 Cell

T helper 22 cells (TH22 cells) are a human skin- and mucosal-homing CD4+ CCR10+ CCR6+ CCR4+ T-lymphocyte subset governed by the aryl hydrocarbon receptor (AhR) that secretes interleukin-22 (IL-22) and TNF-α without IL-17A or IFN-γ to drive antimicrobial peptide expression and epithelial barrier repair.

T helper 22 cells (TH22 cells) are a specialized subset of human skin- and mucosal-homing CD4+ helper T lymphocytes defined phenotypically by surface co-expression of the epidermotropic chemokine receptors CCR10, CCR6, and CCR4 alongside cutaneous lymphocyte-associated antigen (CLA), and functionally by the selective secretion of interleukin-22 (IL-22), tumor necrosis factor-alpha (TNF-α), and interleukin-13 (IL-13) in the complete absence of IL-17A, IL-17F, and interferon-gamma (IFN-γ). Governed transcriptionally by the ligand-activated aryl hydrocarbon receptor (AhR) and STAT3 with low or absent expression of the TH17 master regulator RORγt (RORC), TH22 cells differentiate in response to interleukin-6 (IL-6) and TNF-α produced by activated plasmacytoid and cutaneous dendritic cells. Because the heterodimeric IL-22 receptor (IL-22R1/IL-10R2) is absent from hematopoietic immune cells and expressed on non-hematopoietic keratinocytes, intestinal enterocytes, respiratory epithelial cells, and hepatocytes, TH22 cells function as dedicated lymphoid-to-epithelial communicators that stimulate STAT3 phosphorylation, induce β-defensin and S100A7/A8/A9 antimicrobial peptides, accelerate keratinocyte migration during wound healing, and—when dysregulated—drive epidermal hyperproliferation in psoriasis and atopic dermatitis.

Discovery, Epidermotropic Phenotype, and AhR Transcriptional Control

Identification of Human IL-22+IL-17A− Epidermal-Homing CD4+ T Cells (2009)

Although interleukin-22 (IL-22)—an IL-10 cytokine family member discovered in 2000 by Jean-Christophe Renauld—was initially described in mice as a secondary effector product co-secreted by RORγt+ TH17 cells under IL-23 stimulation, studies of human peripheral blood and healthy skin revealed a major divergence between murine and human CD4+ T-cell compartments. In 2009, three independent teams led by Federica Sallusto and Antonio Lanzavecchia, Carsten Schmidt-Weber and Kilian Eyerich, and Hergen Spits demonstrated that the majority of IL-22-producing CD4+ T cells in human blood and epidermis constitute a stable, autonomous helper lineage (TH22) that neither expresses RORγt nor produces IL-17A, IL-4, or IFN-γ, even after repeated rounds of restimulation in vitro.

Human TH22 cells are programmed with a specialized cutaneous and mucosal homing address code:

  • Cutaneous Lymphocyte-Associated Antigen (CLA): A fucosylated sialyl-Lewisx carbohydrate modification of PSGL-1 that binds E-selectin (CD62E) on dermal postcapillary venules to initiate tethering and rolling into skin.
  • CCR10, CCR4, and CCR6 Triple Chemokine Receptor Signature: CCR10 binds the keratinocyte-restricted homeostatic chemokine CCL27 (CTACK) and mucosal CCL28 (MEC), guiding TH22 cells across the dermo-epidermal junction directly into the basal layer of the epidermis; CCR4 binds dermal microvascular and dendritic-cell CCL17 (TARC) and CCL22 (MDC); and CCR6 binds epithelial CCL20 (MIP-3α).

Cytokine Priming via IL-6 + TNF-α and Suppression by TGF-β

Naive human CD4+ T cells differentiate into TH22 cells when primed by Langerhans cells, dermal conventional dendritic cells, or plasmacytoid dendritic cells (pDCs) in the presence of IL-6 and TNF-α (augmented by IL-1β and IL-23), coupled with vitamin D3 (1,25(OH)2D3, which induces CCR10 expression) and endogenous or microbial aryl hydrocarbon receptor (AhR) agonists:

  1. The TGF-β Bifurcation Gate (TH22 vs. TH17): The decisive microenvironmental switch separating TH22 from TH17 differentiation is transforming growth factor-beta (TGF-β). Whereas TGF-β combined with IL-6 and IL-1β induces RORγt (RORC) and drives TH17 polarization while suppressing IL-22 via the transcriptional repressor c-Maf, priming with IL-6 and TNF-α in the absence of TGF-β activates STAT3 without inducing c-Maf or high RORγt, selectively unlocking the IL22 locus.
  2. Aryl Hydrocarbon Receptor (AhR) Master Regulation: AhR is a cytosolic basic helix-loop-helix/PAS-domain transcription factor that senses planar aromatic ring compounds—including the tryptophan photoproduct 6-formylindolo[3,2-b]carbazole (FICZ) generated in skin by ultraviolet B (UVB) radiation, host kynurenine metabolites, and indole-3-aldehyde produced by commensal skin and gut bacteria (Lactobacillus reuteri, Malassezia). Upon ligand binding, AhR sheds its HSP90 chaperone complex, translocates to the nucleus, heterodimerizes with ARNT (HIF-1β), and binds directly to xenobiotic response elements (XREs) in the IL22 promoter and enhancers, cooperating with phosphorylated STAT3, BNC2, and FOXO4 (and low-level T-bet in murine TH22 counterparts) to drive high-level IL22 transcription while repressing IL17A.
Feature / ParameterT Helper 22 (TH22) CellT Helper 17 (TH17) CellGroup 3 Innate Lymphoid Cell (ILC3 / NKp44+)Skin Resident Memory T (TRM) Cell
Primary Polarizing SignalsIL-6 + TNF-α + AhR ligands (FICZ, indoles) + 1,25(OH)2D3; inhibited by TGF-βTGF-β + IL-6 + IL-1β + IL-23 (TGF-β induces c-Maf, which represses IL22)IL-23 + IL-1β + AhR ligands (innate, antigen-receptor independent)Antigen priming + IL-15 and TGF-β within the epidermis
Core Transcription FactorsAhRhigh, STAT3+, BNC2+, FOXO4+ (RORγt−/low)RORγthigh (RORC), RORα, STAT3, IRF4, BATF, c-MafRORγt+, AhR+, ID2+, Runx3+Runx3, Hobit, Blimp-1, AhR, Notch
Signature Homing ReceptorsCCR10+ (CCL27/28), CCR6+, CCR4+, CLA+CCR6+ (CCL20), CCR4+, CD161+ (CCR10−)CCR6+, NKp44+ (human), NKp46+ (mouse), CD117 (c-Kit)+CD69+, CD103+ (αEβ7), CLA+, CCR10+/−
Secreted Effector ProfileIL-22, TNF-α, IL-13, FGF-1, FGF-5, CCL7 (IL-17A−, IFN-γ−)IL-17A, IL-17F, IL-21, GM-CSF, CCL20 (variable IL-22 in pathogenic subsets)IL-22, GM-CSF, Lymphotoxin (LTα1β2)IFN-γ (CD8+ TRM1), IL-17A (TRM17), or IL-22 (CD4+/CD8+ TRM22)
Target Cell PopulationNon-hematopoietic epithelial cells & fibroblasts only (IL-22R1+)Epithelial, endothelial, stromal, and myeloid cells (IL-17RA/IL-17RC+)Intestinal crypt stem cells (Lgr5+), enterocytes, and stromal cellsLocal infected or malignant keratinocytes and dermal dendritic cells

Unidirectional Lymphoid-to-Epithelial Signaling via IL-22R1/IL-10R2

Exclusive Non-Hematopoietic Expression of IL-22R1 and the IL-22BP Brake

A defining feature of the TH22–IL-22 axis is its strict one-way anatomical directionality: while IL-22 is produced selectively by lymphoid cells (TH22 cells, TH17 cells, γδ T cells, mucosal-associated invariant T cells, and innate lymphoid cells of group 3), its receptor is completely absent from T cells, B cells, NK cells, macrophages, and dendritic cells. The functional IL-22 receptor is a heterodimer of the ubiquitously expressed IL-10R2 (IL-10Rβ) subunit and the high-affinity ligand-binding IL-22R1 (IL-22Rα1) subunit, whose expression is restricted to barrier epithelial cells (epidermal keratinocytes, intestinal enterocytes, Paneth cells, Lgr5+ intestinal crypt stem cells, and bronchial epithelial cells), acinar pancreatic cells, thymic epithelial cells, and hepatocytes.

When TH22-secreted IL-22 binds IL-22R1 (a high-affinity interaction with KD ≈ 10–20 nM), conformational changes recruit IL-10R2, activating receptor-associated JAK1 and TYK2. JAK1/TYK2 phosphorylate cytoplasmic tyrosines on IL-22R1 to trigger robust phosphorylation of STAT3 ( primarily at Tyr705, alongside Ser727 phosphorylation via MAPK/ERK and p38), as well as minor activation of STAT1 and STAT5. To prevent unrestrained epithelial proliferation, dendritic cells and intestinal eosinophils constitutively secrete IL-22 Binding Protein (IL-22BP, encoded by IL22RA2), a soluble decoy receptor that binds free IL-22 with 20- to 1,000-fold higher affinity (KD ≈ 1–10 pM) than membrane-bound IL-22R1, neutralizing excess IL-22 in healthy quiescent tissues until IL-22BP is downregulated by inflammasome-derived IL-18 during acute barrier injury.

Synergistic TNF-α + IL-22 Antimicrobial and Wound-Healing Programs

Because TH22 cells co-secrete IL-22 alongside TNF-α and fibroblast growth factors (FGF-1, FGF-5), their target keratinocytes and enterocytes integrate STAT3 signaling (from IL-22) with NF-κB and AP-1 signaling (from TNF-α), driving four protective barrier programs:

  1. Antimicrobial Peptide (AMP) Induction: Synergistic STAT3 + NF-κB activation induces high-level transcription and secretion of cationic human β-defensin 2 (hBD-2 / DEFB4A), hBD-3 (DEFB103A), psoriasin (S100A7), calprotectin (S100A8/S100A9, which chelates extracellular Zn2+ and Mn2+ to starve bacteria and fungi), and C-type antimicrobial lectins RegIIIβ and RegIIIγ in the gut.
  2. Epithelial Stem Cell Survival and Wound Re-Epithelialization: In skin wounds and radiation- or graft-versus-host-damaged intestinal crypts, IL-22–STAT3 upregulates anti-apoptotic Bcl-2, Bcl-xL, and Mcl-1 alongside cell-cycle regulators Cyclin D1 and c-Myc, stimulating keratinocyte migration across dermal provisional matrices, extracellular matrix remodeling by fibroblasts, and regeneration of Lgr5+ intestinal stem cells.
  3. Mucin and Fucosylation Reinforcement: In the gastrointestinal and respiratory tracts, IL-22 stimulates MUC1, MUC3, MUC10, and MUC13 mucin synthesis and induces epithelial fucosyltransferase 2 (FUT2), adding α(1,2)-linked fucose residues to luminal mucin glycans that nourish beneficial commensals of the human microbiome while blocking colonization by Citrobacter rodentium, Salmonella enterica, and Klebsiella pneumoniae.

Clinical Roles in Psoriasis, Atopic Dermatitis, and Mucosal Infection

Whereas acute TH22 activation repairs damaged skin and gut barriers, chronic overproduction of IL-22 and TNF-α by epidermotropic TH22 cells (and epidermal CD4+/CD8+ Tc22 tissue-resident memory T cells) disrupts terminal keratinocyte differentiation:

  • Atopic Dermatitis and Psoriasis: As demonstrated by Emma Guttman-Yassky, James G. Krueger, and Kilian Eyerich, IL-22 inhibits key genes required for terminal cornified envelope assembly—downregulating filaggrin (FLG), loricrin (LOR), involucrin (IVL), and keratin 1/10—while driving keratinocyte hyperplasia (acanthosis), retained nuclei in the stratum corneum (parakeratosis), and spongiosis. Whereas plaque psoriasis is driven by a dual TH17 + TH22 (IL-17A + IL-22 + TNF-α) circuit that recruits neutrophils into Munro's microabscesses, chronic atopic dermatitis (particularly in intrinsic and Asian atopic dermatitis endotypes) features a prominent TH2 + TH22 (IL-13 + IL-22) signature in which IL-22 drives pronounced epidermal thickening (lichenification) and filaggrin deficiency without neutrophilic pustules. Monoclonal antibody blockade of IL-22R1 or neutralization of IL-22 (fezakinumab) significantly reverses epidermal hyperplasia and restores barrier transcriptomes in refractory, baseline-IL-22high atopic dermatitis.
  • HIV Mucosal Depletion and Bacterial Translocation: Conversely, during acute human immunodeficiency virus (HIV-1) infection, CCR5+CCR6+ TH22 and TH17 cells in the gastrointestinal lamina propria are preferentially infected and depleted. Loss of mucosal TH22-derived IL-22 compromises enterocyte tight junctions and RegIIIγ secretion, enabling systemic microbial translocation of Gram-negative lipopolysaccharide that fuels chronic immune activation in untreated HIV disease.

Frequently Asked Questions

How do TH22 cells differ from TH17 cells?

Although both subsets participate in epithelial barrier immunity and share expression of CCR6 and STAT3, TH17 cells depend on TGF-β and the master transcription factor RORγt (RORC) to secrete IL-17A and IL-17F (which recruit neutrophils to sites of extracellular bacterial or fungal infection). In contrast, TH22 differentiation is inhibited by TGF-β (via c-Maf) and is driven instead by IL-6, TNF-α, and the aryl hydrocarbon receptor (AhR). Human TH22 cells express the skin-homing receptor CCR10, have low or absent RORγt, and secrete IL-22 and TNF-α without IL-17A, promoting antimicrobial peptide production and tissue regeneration without triggering destructive neutrophilic inflammation.

Why does interleukin-22 act on skin and gut cells without directly activating immune cells?

The functional IL-22 receptor is a heterodimer composed of IL-10R2 and IL-22R1. While IL-10R2 is expressed ubiquitously across all cell types, expression of the high-affinity ligand-binding chain IL-22R1 is restricted to non-hematopoietic barrier epithelial cells (keratinocytes, intestinal enterocytes, respiratory epithelium), hepatocytes, and pancreatic acinar cells, and is completely absent from T cells, B cells, macrophages, and dendritic cells. This receptor distribution creates a unidirectional communication channel from TH22 lymphocytes to tissue parenchymal cells.

How does ultraviolet light or the skin microbiome activate TH22 cells via AhR?

TH22 cells express high levels of the aryl hydrocarbon receptor (AhR), a ligand-activated transcription factor. When human skin is exposed to ultraviolet B (UVB) radiation, intracellular free L-tryptophan undergoes photo-oxidation into 6-formylindolo[3,2-b]carbazole (FICZ), a picomolar-affinity endogenous AhR agonist; similarly, commensal skin and gut microbes metabolize dietary tryptophan into indole-3-aldehyde and related indoles. Binding of FICZ or microbial indoles causes AhR to translocate to the nucleus, dimerize with ARNT, and bind xenobiotic response elements in the IL22 promoter, amplifying IL-22 secretion to reinforce epidermal barrier integrity.

References

  1. Duhen, T., Geiger, R., Jarrossay, D., Lanzavecchia, A., & Sallusto, F. (2009). "Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells." Nature Immunology, 10(8), 857–863. https://doi.org/10.1038/ni.1767
  2. Trifari, S., Kaplan, C. D., Tran, E. H., Crellin, N. K., & Spits, H. (2009). "Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from TH-17, TH1 and TH2 cells." Nature Immunology, 10(8), 864–871. https://doi.org/10.1038/ni.1770
  3. Eyerich, S., Eyerich, K., Pennino, D., Carbone, T., Nasorri, F., Pallotta, S., Cianfarani, F., Odorisio, T., Traidl-Hoffmann, C., Behrendt, H., Durham, S. R., Schmidt-Weber, C. B., & Cavani, A. (2009). "Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling." Journal of Clinical Investigation, 119(12), 3573–3585. https://doi.org/10.1172/JCI40202
  4. Dudakov, J. A., Hanash, A. M., & van den Brink, M. R. M. (2015). "Interleukin-22: immunobiology and pathology." Annual Review of Immunology, 33, 747–785. https://doi.org/10.1146/annurev-immunol-032414-112123
🧬 Support Open Science
Explore interactive science games on LowKey Games or browse scientific apparel & accessories in the CRV Science Shop.
💡 Spot an inaccuracy or have primary literature to expand this article?
Submit a citation or revision note using your shared CRV Science / LowKey Games profile ID.
Suggest Revision